# JW Pharmaceutical clinical trials: 77 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 77 trials with JW Pharmaceutical as lead sponsor, 6 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by JW Pharmaceutical: 77 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/jw-pharmaceutical

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 77
- Recruiting or not yet: 6
- Read on: November 19, 2026

## Trials

The 25 newest of 77, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| April 13, 2026 | NCT07523971 | Efficacy and Safety of Pitavastatin/Ezetimibe in Dyslipidemia Patients With Metabolic Syndrome: An Observational Study | JW Pharmaceutical | Observational | Recruiting | Dyslipidemias | 10,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07523971) |
| April 7, 2026 | NCT07514780 | To Evaluate the Safety, Pharmacokinetic and Pharmacodynamics of JW0061 in Healthy Volunteers | JW Pharmaceutical | Phase 1 | Recruiting | Healthy | 104 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07514780) |
| March 3, 2026 | NCT07445542 | Efficacy and Safety of Pitavastatin/Ezetimibe After Switching From Statin Monotherapy to Pitavastatin/Ezetimibe in Patients With... | JW Pharmaceutical | Observational | Completed | Hypercholesterolemia | 6,927 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07445542) |
| March 2, 2026 | NCT07442630 | Long-term Comparison of Pitavastatin/Ezetimibe and Pitavastatin in Patients With Hypercholesterolemia and Elevated Triglycerides | JW Pharmaceutical | Phase 4 | Active not recruiting | Hypercholesterolemia | 88 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07442630) |
| March 2, 2026 | NCT07442006 | Glycemic Variability of Combination Therapies in T2DM | JW Pharmaceutical | Phase 4 | Recruiting | Type 2 Diabetes Mellitus (T2DM) | 178 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07442006) |
| February 3, 2026 | NCT07382778 | Efficacy and Safety of Livalozet® in Hypercholesterolemic Patients With and Without Diabetes | JW Pharmaceutical | Observational | Completed | Hypercholesterolemia | 1,538 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07382778) |
| January 30, 2026 | NCT07378098 | to Evaluate the Efficacy and Safety of KLH-2109 in Patients With Uterine Fibroids and Menorrhagia | JW Pharmaceutical | Phase 3 | Recruiting | Menorrhagia, Uterine Fibroids | 254 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07378098) |
| January 28, 2026 | NCT07374406 | To Evaluate the Safety and Pharmacokinetic Characteristics in Healthy Volunteers | JW Pharmaceutical | Phase 1 | Completed | Healthy | 34 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07374406) |
| June 25, 2025 | NCT07036458 | To Evaluate the Mass Balance Recovery, Metabolite Profile and Metabolite Identification in Healthy Male Subjects | JW Pharmaceutical | Phase 1 | Completed | Healthy Male Adults | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07036458) |
| May 2, 2025 | NCT06955104 | Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of JW0108+C2407 in Patients With Dyslipidemia | JW Pharmaceutical | Phase 3 | Completed | Dyslipidemia | 145 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06955104) |
| February 10, 2025 | NCT06816719 | To Evaluate the Safety and PK Characteristics in Healthy Volunteers-JW24107 | JW Pharmaceutical | Phase 1 | Completed | Healthy | 47 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06816719) |
| January 1, 2025 | NCT06754943 | To Evaluate the Safety and PK Characteristics After Co-administration of JW0104 and C2402 and Administration of JW0105 | JW Pharmaceutical | Phase 1 | Completed | Healthy | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06754943) |
| November 25, 2024 | NCT06703710 | To Evaluate the Safety/Tolerability and Pharmacokinetic Characteristics in Healthy Volunteers | JW Pharmaceutical | Phase 1 | Recruiting | Healthy | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06703710) |
| October 30, 2024 | NCT06665425 | PK,PD and DDI of Epaminurad and C2406 in Healthy Volunteers | JW Pharmaceutical | Phase 1 | Completed | Healthy Volunteers | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06665425) |
| October 16, 2024 | NCT06643130 | Evaluate the Efficacy and Safety of Co-administration of JW0104+C2402 in Patients With Hypertension and Dyslipidemia | JW Pharmaceutical | Phase 3 | Recruiting | Hypertension, Dyslipidemia | 162 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06643130) |
| May 30, 2024 | NCT06435442 | PK,PD and DDI of Epaminurad and Naproxen in Healthy Volunteers | JW Pharmaceutical | Phase 1 | Completed | Healthy | 57 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06435442) |
| April 22, 2024 | NCT06378684 | To Evaluate the Safety and Pharmacokinetic Interactions in Healthy Volunteers | JW Pharmaceutical | Phase 1 | Completed | Healthy | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06378684) |
| April 11, 2024 | NCT06361277 | To Evaluate the Pharmacokinetic Characteristics and Safety in Healthy Volunteers | JW Pharmaceutical | Phase 1 | Completed | Healthy | 56 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06361277) |
| April 9, 2024 | NCT06355349 | To Evaluate the Safety and PK Characteristics in Healthy Volunteers | JW Pharmaceutical | Phase 1 | Completed | Healthy | 46 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06355349) |
| April 18, 2023 | NCT05815901 | A Therapeutic Confirmatory Study of Epaminurad Versus Febuxostat in Gout Patients | JW Pharmaceutical | Phase 3 | Completed | Gout | 612 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05815901) |
| April 14, 2023 | NCT05814406 | To Evaluate the Efficacy and Safety of JW0201 Added on in Patients With T2DM | JW Pharmaceutical | Phase 3 | Completed | Type 2 Diabetes Mellitus | 196 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05814406) |
| April 14, 2023 | NCT05814393 | To Evaluate the Efficacy and Safety of JW0201 Added on in Patients With Type 2 Diabetes Mellitus | JW Pharmaceutical | Phase 3 | Completed | Type 2 Diabetes Mellitus | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05814393) |
| March 24, 2023 | NCT05784155 | To Evaluate the PK, PD, Safety and Drug Tolerance of JW0302 in Healthy Volunteers | JW Pharmaceutical | Phase 1 | Completed | Healthy | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05784155) |
| August 19, 2022 | NCT05508776 | A Trial to Evaluate the Effect of LEO 152020 on the Heart of Healthy People | JW Pharmaceutical | Phase 1 | Completed | Healthy Volunteers, Cardiac Repolarisation | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05508776) |
| July 19, 2022 | NCT05463497 | To Evaluate the Pharmacokinetic Drug Interactions, Safety and Drug Tolerance in Healthy Volunteers | JW Pharmaceutical | Phase 1 | Completed | Healthy | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05463497) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 26 |
| Phase 1/2 | 1 |
| Phase 2 | 6 |
| Phase 3 | 16 |
| Phase 4 | 17 |
| Observational | 11 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 65 |
| Recruiting | 6 |
| Unknown | 3 |
| Terminated | 1 |
| Active not recruiting | 1 |
| Withdrawn | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Diabetes Mellitus, Type 2 | 9 |
| Hypercholesterolemia | 7 |
| Dyslipidemias | 6 |
| Hypertension | 5 |
| Prostatic Hyperplasia | 4 |
| Gout | 4 |
| Hyperlipidemias | 4 |
| Metabolic Syndrome | 2 |
| Diabetes Mellitus | 2 |
| Arthritis, Rheumatoid | 2 |
| Leukemia, Myeloid, Acute | 2 |
| Erectile Dysfunction | 2 |
| Anemia, Iron-Deficiency | 2 |
| Hyperuricemia | 2 |
| Ureterolithiasis | 1 |
| Leukemia, Myelomonocytic, Chronic | 1 |
| Myelodysplastic Syndromes | 1 |
| Primary Myelofibrosis | 1 |
| Nocturia | 1 |
| Kidney Failure, Chronic | 1 |
| Anemia | 1 |
| Menorrhagia | 1 |
| Leiomyoma | 1 |
| Renal Insufficiency | 1 |
| Heart Failure | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Dentistry schools in the United States](https://specstream.ai/data/businesses/dentistry-schools/united-states)
- [Audiology clinics in the United States](https://specstream.ai/data/businesses/audiology-clinics/united-states)
- [Shoe factory manufacturers in the United States](https://specstream.ai/data/businesses/shoe-factory-manufacturers/united-states)
- [Medical transportation companies in the United States](https://specstream.ai/data/businesses/medical-transportation-companies/united-states)
- [Fire protection companies in the United States](https://specstream.ai/data/businesses/fire-protection-companies/united-states)
